LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1. / Pedersen, A; Hougen, H P; Klausen, B; Winther, K.

I: Ugeskrift for Laeger, Bind 153, Nr. 37, 1991, s. 2557-61.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Pedersen, A, Hougen, HP, Klausen, B & Winther, K 1991, 'LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1', Ugeskrift for Laeger, bind 153, nr. 37, s. 2557-61.

APA

Pedersen, A., Hougen, H. P., Klausen, B., & Winther, K. (1991). LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1. Ugeskrift for Laeger, 153(37), 2557-61.

Vancouver

Pedersen A, Hougen HP, Klausen B, Winther K. LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1. Ugeskrift for Laeger. 1991;153(37):2557-61.

Author

Pedersen, A ; Hougen, H P ; Klausen, B ; Winther, K. / LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1. I: Ugeskrift for Laeger. 1991 ; Bind 153, Nr. 37. s. 2557-61.

Bibtex

@article{c7fd4bcf0a884e298c851b2e7425ad5e,
title = "LongoVital i forebyggelsen af recidiverende aft{\o}s stomatit. 1",
abstract = "LongoVital (LV) (DK. reg. no. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during daily intake of LV for six months as compared with placebo in a double-blind, randomised clinical, cross-over 1-year study. The population comprised 29 otherwise healthy minor RAU patients (18F, 11M) mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on treatment with LV during the latter four of the six months (p less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favour of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.",
keywords = "Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Plant Extracts, Recurrence, Stomatitis, Aphthous, Tablets, Vitamins",
author = "A Pedersen and Hougen, {H P} and B Klausen and K Winther",
year = "1991",
language = "Dansk",
volume = "153",
pages = "2557--61",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "37",

}

RIS

TY - JOUR

T1 - LongoVital i forebyggelsen af recidiverende aftøs stomatit. 1

AU - Pedersen, A

AU - Hougen, H P

AU - Klausen, B

AU - Winther, K

PY - 1991

Y1 - 1991

N2 - LongoVital (LV) (DK. reg. no. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during daily intake of LV for six months as compared with placebo in a double-blind, randomised clinical, cross-over 1-year study. The population comprised 29 otherwise healthy minor RAU patients (18F, 11M) mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on treatment with LV during the latter four of the six months (p less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favour of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.

AB - LongoVital (LV) (DK. reg. no. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during daily intake of LV for six months as compared with placebo in a double-blind, randomised clinical, cross-over 1-year study. The population comprised 29 otherwise healthy minor RAU patients (18F, 11M) mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on treatment with LV during the latter four of the six months (p less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favour of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.

KW - Adult

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Plant Extracts

KW - Recurrence

KW - Stomatitis, Aphthous

KW - Tablets

KW - Vitamins

M3 - Tidsskriftartikel

C2 - 1949257

VL - 153

SP - 2557

EP - 2561

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 37

ER -

ID: 44355053